Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 17/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179483 | 0.89 | F2 (0.47) | F2PRSS1SCN5ASCN3ACHRM3 | |
| Hydrochloric Acid SCHEMBL6093262 | 0.88 | F2 (0.47) | F2PRSS1SCN5ASCN3ACHRM3 | |
| SCHEMBL6093041 | 0.86 | KDM4E (0.39) | F2XIAPMLX | |
| SCHEMBL6095258 | 0.86 | KDM4E (0.39) | F2XIAPMLX | |
| SCHEMBL6094199 | 0.84 | F2 (0.46) | F2PRSS1XIAPMLXSCN5A | |
| SCHEMBL6179624 | 0.83 | F2 (0.41) | F2PRSS1SCN5ASCN3ACHRM3 | |
| SCHEMBL6093180 | 0.79 | TAAR1 (0.41) | F2XIAPSCN5ASCN3A | |
| SCHEMBL6096030 | 0.76 | TMPRSS11D (0.46) | F2PRSS1 | |
| Hydrochloric Acid SCHEMBL6094357 | 0.76 | F2 (0.43) | F2PRSS1 | |
| SCHEMBL6178057 | 0.74 | KDM4E (0.41) | F2XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1287018-B1 | THROMBIN INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-01-19 | — | — | EP | claimed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | claimed |
| EP-1287018-A2 | THROMBIN INHIBITORS | Lek Pharmaceutical and Chemical Co. D.D. (SI) | 2003-03-05 | — | — | EP | claimed |
| WO-2001085760-A1 | THROMBIN INHIBITORS | LEK PHARMACEUTICAL & CHEMICAL CO. DD (SI) | 2001-11-15 | — | — | WO | claimed |
| US-7112590-B2 | Thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2006-09-26 | — | — | US | disclosed |
| EP-1287018-B1 | THROMBIN INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-01-19 | — | — | EP | disclosed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | disclosed |
| EP-1287018-A2 | THROMBIN INHIBITORS | Lek Pharmaceutical and Chemical Co. D.D. (SI) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001085760-A1 | THROMBIN INHIBITORS | LEK PHARMACEUTICAL & CHEMICAL CO. DD (SI) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191139-A1 | Thrombin inhibitors | TFPI, F2, SERPINC1 | F2 2/4885PRSS1 86/4885XIAP 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.